JB Chemicals & Pharmaceuticals Limited — PPTs, 16-01-2026: Investor Presentation

JB Pharma reported strong Q3 FY26 revenue of 1,065 Cr, up 11% YoY, with 9M FY26 revenue reaching 3,244 Cr, up 9%. Domestic formulations grew 10% to 620 Cr, outpacing the Indian pharma market. International business climbed 12% to 445 Cr, fueled by a 20% surge in international formulations.

The company's focus on cost optimization, a favorable product mix, and operational efficiencies helped improve operating margins. Future strategy centers on strengthening flagship brands, accelerating chronic therapy growth, and expanding its CDMO business.

Six JB Pharma brands are now among the Top 300 in India. The Sporlac franchise nearly doubled to 160 Cr, and the Razel franchise surpassed 100 Cr. The Ophthalmology portfolio also saw robust 10% growth to 230 Cr.

Key financials show Q3 FY26 Operating EBITDA up 13% to 305 Cr (28.7% margin), and Net Profit jumping 22% to 198 Cr. For 9M FY26, Operating EBITDA hit 955 Cr (29.4% margin), with Net Profit at 608 Cr, up 18%.

Management is confident in delivering profitable growth, backed by a strong balance sheet. CDMO business momentum is expected to continue into Q4 FY26.